Principal Financial Group’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$40.3M Buy
239,193
+1,032
+0.4% +$153K 0.02% 605
2026
Q1
$31.4M Buy
238,161
+11,784
+5% +$1.56M 0.02% 668
2025
Q4
$32.1M Sell
226,377
-5,386
-2% -$780K 0.02% 632
2025
Q3
$32.5M Sell
231,763
-11,967
-5% -$1.62M 0.02% 628
2025
Q2
$30.6M Sell
243,730
-4,690
-2% -$538K 0.02% 633
2025
Q1
$27.5M Sell
248,420
-4,049
-2% -$513K 0.02% 654
2024
Q4
$34.5M Sell
252,469
-717
-0.3% -$88.7K 0.02% 586
2024
Q3
$29.2M Sell
253,186
-120,576
-32% -$16.5M 0.02% 651
2024
Q2
$51.5M Sell
373,762
-44,913
-11% -$6.16M 0.03% 451
2024
Q1
$57.7M Buy
418,675
+430
+0.1% +$58.7K 0.03% 434
2023
Q4
$55.1M Buy
418,245
+40,289
+11% +$4.64M 0.04% 410
2023
Q3
$42.5M Sell
377,956
-5,978
-2% -$629K 0.03% 463
2023
Q2
$36.2M Sell
383,934
-3,648
-0.9% -$356K 0.02% 546
2023
Q1
$39.2M Sell
387,582
-13,082
-3% -$1.36M 0.03% 509
2022
Q4
$47.9M Buy
400,664
+11,659
+3% +$1.37M 0.04% 425
2022
Q3
$41.3M Sell
389,005
-3,502
-0.9% -$355K 0.03% 444
2022
Q2
$38.3M Buy
392,507
+67,568
+21% +$6.24M 0.03% 505
2022
Q1
$30.5M Sell
324,939
-3,520
-1% -$298K 0.02% 655
2021
Q4
$28M Sell
328,459
-3,313
-1% -$305K 0.02% 725
2021
Q3
$31.8M Sell
331,772
-1,967
-0.6% -$186K 0.02% 623
2021
Q2
$32.5M Buy
333,739
+5,912
+2% +$567K 0.02% 633
2021
Q1
$31.9M Buy
327,827
+316,575
+2,813% +$33.2M 0.02% 611
2020
Q4
$1.08M Sell
11,252
-362
-3% -$35K ﹤0.01% 1929
2020
Q3
$1.12M Sell
11,614
-2,072
-15% -$240K ﹤0.01% 1850
2020
Q2
$1.67M Buy
13,686
+3,369
+33% +$372K ﹤0.01% 1734
2020
Q1
$893K Buy
10,317
+400
+4% +$39.1K ﹤0.01% 1750
2019
Q4
$1.07M Sell
9,917
-47,178
-83% -$4.94M ﹤0.01% 1823
2019
Q3
$5.14M Buy
57,095
+2,381
+4% +$222K ﹤0.01% 1507
2019
Q2
$4.62M Buy
54,714
+519
+1% +$42.6K ﹤0.01% 1553
2019
Q1
$4.78M Buy
54,195
+10
+0% +$836 ﹤0.01% 1557
2018
Q4
$3.87M Sell
54,185
-29,816
-35% -$2.86M ﹤0.01% 1588
2018
Q3
$10.3M Sell
84,001
-8,082
-9% -$917K 0.01% 1306
2018
Q2
$9.05M Buy
92,083
+13,127
+17% +$1.18M 0.01% 1363
2018
Q1
$6.55M Buy
78,956
+1,234
+2% +$104K 0.01% 1461
2017
Q4
$6.03M Buy
77,722
+882
+1% +$60.2K 0.01% 1499
2017
Q3
$4.71M Sell
76,840
-839
-1% -$44.3K ﹤0.01% 1575
2017
Q2
$3.57M Buy
77,679
+1,728
+2% +$83.8K ﹤0.01% 1644
2017
Q1
$3.29M Sell
75,951
-194
-0.3% -$8.31K ﹤0.01% 1649
2016
Q4
$2.95M Buy
76,145
+5,386
+8% +$244K ﹤0.01% 1653
2016
Q3
$3.58M Sell
70,759
-82,682
-54% -$4.12M ﹤0.01% 1572
2016
Q2
$6.97M Sell
153,441
-7,450
-5% -$343K 0.01% 1276
2016
Q1
$6.36M Buy
160,891
+658
+0.4% +$26.1K 0.01% 1262
2015
Q4
$9.06M Buy
160,233
+449
+0.3% +$22.8K 0.01% 1024
2015
Q3
$6.36M Buy
159,784
+145,057
+985% +$7.01M 0.01% 1215
2015
Q2
$703K Buy
14,727
+2,632
+22% +$112K ﹤0.01% 1822
2015
Q1
$480K Sell
12,095
-154
-1% -$5.51K ﹤0.01% 1847
2014
Q4
$274K Sell
12,249
-1,675
-12% -$31.7K ﹤0.01% 1953
2014
Q3
$218K Hold
13,924
﹤0.01% 2006
2014
Q2
$207K Sell
13,924
-4,415
-24% -$62.3K ﹤0.01% 2080
2014
Q1
$295K Buy
+18,339
New +$314K ﹤0.01% 1999
2013
Q4
Sell
-21,277
Closed -$241K 2297
2013
Q3
$241K Sell
21,277
-2,059
-9% -$28.3K ﹤0.01% 2037
2013
Q2
$312K Buy
+23,336
New +$287K ﹤0.01% 1926

Other funds holding NBIX

Principal Financial Group's NBIX Position: Q2 2026 in Review

Principal Financial Group increased its Neurocrine Biosciences (NBIX) stake by 0.43% in Q2 2026, buying an estimated $153K and bringing the position to 239,193 shares worth $40.3M. The position accounts for 0.02% of the portfolio, ranked #605.

Principal Financial Group first reported a position in NBIX in Q2 2013 and has held it in 52 quarters since. The position peaked at $57.7M in Q1 2024. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Principal Financial Group held 239,193 shares of Neurocrine Biosciences worth $40.3M as of Q2 2026.
  • Principal Financial Group bought 1,032 Neurocrine Biosciences shares in Q2 2026, an estimated $153K.
  • Neurocrine Biosciences made up 0.02% of Principal Financial Group's portfolio in Q2 2026, its #605 holding.
  • Principal Financial Group first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 52 quarters since.
  • Principal Financial Group's Neurocrine Biosciences position peaked at $57.7M in Q1 2024.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.